Global Gabapentin Market Growth 2025-2031

Global Gabapentin Market Growth 2025-2031

The global Gabapentin market size is predicted to grow from US$ 1563 million in 2025 to US$ 1746 million in 2031; it is expected to grow at a CAGR of 1.9% from 2025 to 2031.

Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain.

Global Gabapentin key players include Novartis, TEVA, Mylan, Pfizer, etc. Global top four manufacturers hold a share about 20%.

North America is the largest market, with a share over 30%, followed by Asia-Pacific, and Europe, both have a share about 50 percent.

In terms of product, Capsule is the largest segment, with a share about 55%. And in terms of application, the largest application is Epilepsy, followed by Neuropathic Pain, Restless Legs Syndrome, etc.

LP Information, Inc. (LPI) ' newest research report, the “Gabapentin Industry Forecast” looks at past sales and reviews total world Gabapentin sales in 2024, providing a comprehensive analysis by region and market sector of projected Gabapentin sales for 2025 through 2031. With Gabapentin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Gabapentin industry.

This Insight Report provides a comprehensive analysis of the global Gabapentin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gabapentin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gabapentin market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gabapentin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gabapentin.

This report presents a comprehensive overview, market shares, and growth opportunities of Gabapentin market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Capsule
Tablet

Segmentation by Application:
Epilepsy
Neuropathic Pain
Restless Legs Syndrome
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Pfizer
Assertio Therapeutics
TEVA
Mylan
Arbor Pharma
Novartis
Apotex
Sun Pharmaceutical
Aurobindo Pharma
Intas
Amneal
Marksans Pharma
Glenmark
Alkem
Jiangsu Enhua
Jiangsu Hengrui
Sailike

Key Questions Addressed in this Report

What is the 10-year outlook for the global Gabapentin market?

What factors are driving Gabapentin market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Gabapentin market opportunities vary by end market size?

How does Gabapentin break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.